Dr Luke Selth’s research focuses on improving prognosis for prostate cancer, a leading cause of cancer-related death in the Western World. Current tests cannot accurately distinguish between patients with tumours that are likely to metastasise and require aggressive early treatment and those with slow-growing tumours that do not require treatment. Luke’s research has identified a new group of blood biomarkers, called microRNAs, that can be used to predict whether a particular cancer requires treatment. These markers have the potential to revolutionise the clinical management of prostate cancer. His research has also shown that some of these microRNAs promote prostate cancer metastasis and could be new drug targets.